Akari Therapeutics (AKTX) Retained Earnings (2011 - 2026)

Akari Therapeutics (AKTX) has reported Retained Earnings for 16 consecutive years, with -$279.0 million the latest figure, recorded in Q1 2026.

• Quarterly Retained Earnings fell 11.16% year-over-year to -$279.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$279.0 million (down 11.16% YoY) and the FY2025 annual result came in at -$264.6 million, down 7.0% from the prior year.
• Retained Earnings fell to -$279.0 million in Q1 2026 per AKTX's latest filing, from -$264.6 million in the prior quarter.
• Over the last five years, Retained Earnings for AKTX reached as high as -$210.6 million in Q2 2022 and fell as low as -$279.0 million in Q1 2026.
• A 5-year average of -$242.1 million and a median of -$243.5 million in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings decreased 4.6% — and 2026, when it declined 11.16%.
• Year by year, Retained Earnings stood at -$217.5 million in 2022, then dropped by 4.6% to -$227.5 million in 2023, then slipped by 8.7% to -$247.3 million in 2024, then declined by 7.0% to -$264.6 million in 2025, then slipped by 5.46% to -$279.0 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$279.0 million, -$264.6 million, and -$259.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.